b.value AG invests in early-stage biotechnology, chemistry and advanced materials startups and focuses on companies and founder teams in Germany, Austria, and Switzerland. Areas of interest are health and nutrition, resource efficiency, and digitalization. b.value does not invest in pharmaceutical developments. b.value AG is building a long-term portfolio of fast-growing, young biotech companies whose products and business models include disruptive innovation and high scalability, and with teams that are expected to develop particularly positively through their entrepreneurial skills. The b.value AG acquires majority and minority interests. In almost all cases, it invests in the Seed Stage together with other co-investors (serial entrepreneurs, business angels, venture capital funds), who share our commitments through know-how and equity investments. The needs of the company defines the kind of b.value investments. Besides venture capital, the b.value AG offers start-ups comprehensive consulting and active support in their development (company building) by its portfolio company b.experts GmbH (www.bexperts.de). The b.experts GmbH accompanies start-ups in their development on a partnership basis.